PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes

Literature Cited

1. Benjamin EJ, Blaha MJ, Chiuve SE. 1.  et al. 2017. Heart disease and stroke statistics—2017 update: a report from the American Heart Association. Circulation 135:e146–e603 [Google Scholar]
2. Stone NJ, Robinson JG, Lichtenstein AH. 2.  et al. 2014. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:S1–45 [Google Scholar]
3. Silverman MG, Ference BA, Im K. 3.  et al. 2016. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 316:1289–97 [Google Scholar]
4. Collins R, Reith C, Emberson J. 4.  et al. 2016. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388:2532–61 [Google Scholar]
5. Boden WE, Probstfield JL, Anderson T. 5.  et al. 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365:2255–67 [Google Scholar]
6. Barter PJ, Caulfield M, Eriksson M. 6.  et al. 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357:2109–22 [Google Scholar]
7. Kosmas CE, DeJesus E, Rosario D, Vittorio TJ. 7.  2016. CETP inhibition: past failures and future hopes. Clin. Med. Insights Cardiol. 10:37–42 [Google Scholar]
8. Cannon CP, Blazing MA, Giugliano RP. 8.  et al. 2015. Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med. 372:2387–97 [Google Scholar]
9. Wong ND, Chuang J, Zhao Y, Rosenblit PD. 9.  2015. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009–2010. J. Clin. Lipidol. 9:525–32 [Google Scholar]
10. Sirimarco G, Labreuche J, Bruckert E. 10.  et al. 2014. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke 45:1429–36 [Google Scholar]
11. Karalis DG, Victor B, Ahedor L, Liu L. 11.  2012. Use of lipid-lowering medications and the likelihood of achieving optimal LDL-cholesterol goals in coronary artery disease patients. Cholesterol 2012:861924 [Google Scholar]
12. Seidah NG, Benjannet S, Wickham L. 12.  et al. 2003. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. PNAS 100:928–33 [Google Scholar]
13. Abifadel M, Rabes JP, Devillers M. 13.  et al. 2009. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum. Mutat. 30:520–29 [Google Scholar]
14. Abifadel M, Varret M, Rabes JP. 14.  et al. 2003. Mutations in PCSK9 cause autosomal dominant hyper-cholesterolemia. Nat. Genet. 34:154–56 [Google Scholar]
15. Timms KM, Wagner S, Samuels ME. 15.  et al. 2004. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum. Genet. 114:349–53 [Google Scholar]
16. Burke AC, Dron JS, Hegele RA, Huff MW. 16.  2017. PCSK9: Regulation and target for drug development for dyslipidemia. Annu. Rev. Pharmacol. Toxicol. 57:223–44 [Google Scholar]
17. Maxwell KN, Breslow JL. 17.  2004. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. PNAS 101:7100–5 [Google Scholar]
18. Park SW, Moon YA, Horton JD. 18.  2004. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279:50630–38 [Google Scholar]
19. Cohen J, Pertsemlidis A, Kotowski IK. 19.  et al. 2005. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37:161–65 [Google Scholar]
20. Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH. 20.  2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354:1264–72 [Google Scholar]
21. Bergeron N, Phan BA, Ding Y. 21.  et al. 2015. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk. Circulation 132:1648–66 [Google Scholar]
22. Seidah NG, Zuhier A, Chetien M, Mbikay M. 22.  2014. PCKS: a key modulator of cardiovascular health. Circ. Res. 114:1022–36 [Google Scholar]
23. Rashid S, Tavori H, Brown PE. 23.  et al. 2014. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation 130:431–41 [Google Scholar]
24. Sible AM, Nawarskas JJ, Anderson JR. 24.  2016. PCSK9 inhibitors: an innovative approach to treating hyperlipidemia. Cardiol. Rev. 24:141–52 [Google Scholar]
25. Dias CS, Shaywitz AJ, Wasserman SM. 25.  et al. 2012. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J. Am. Coll. Cardiol. 60:1888–98 [Google Scholar]
26. Stein EA, Mellis S, Yancopoulos GD. 26.  et al. 2012. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366:1108–18 [Google Scholar]
27. Mitchell T, Chao G, Sitkoff D. 27.  et al. 2014. Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J. Pharmacol. Exp. Ther. 350:412–24 [Google Scholar]
28. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S. 28.  et al. 2014. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 383:60–68 [Google Scholar]
29. Blom DJ, Hala T, Bolognese M. 29.  et al. 2014. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl. J. Med. 370:1809–19 [Google Scholar]
30. Sabatine MS, Giugliano RP, Keech AC. 30.  et al. 2017. Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376:1713–22 [Google Scholar]
31. Koren MJ, Scott R, Kim JB. 31.  et al. 2012. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 380:1995–2006 [Google Scholar]
32. Giugliano RP, Desai NR, Kohli P. 32.  et al. 2012. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 380:2007–17 [Google Scholar]
33. Sullivan D, Olsson AG, Scott R. 33.  et al. 2012. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 308:1–10 [Google Scholar]
34. Raal F, Scott R, Somaratne R. 34.  et al. 2012. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 126:2408–17 [Google Scholar]
35. Raal FJ, Stein EA, Dufour R. 35.  et al. 2015. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385:331–40 [Google Scholar]
36. Stein EA, Honarpour N, Wasserman SM. 36.  et al. 2013. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 128:2113–20 [Google Scholar]
37. Raal FJ, Honarpour N, Blom DJ. 37.  et al. 2015. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 385:341–50 [Google Scholar]
38. Koren MJ, Giugliano RP, Raal FJ. 38.  et al. 2014. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation 129:234–43 [Google Scholar]
39. 39. Food and Drug Administration. 2015. FDA approves Praluent to treat certain patients with high cholesterol: first in a new class of injectable cholesterol-lowering drugs News release. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm455883.htm. Accessed Apr. 8, 2015 [Google Scholar]
40. Robinson JG, Farnier M, Krempf M. 40.  et al. 2015. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372:1489–99 [Google Scholar]
41. Kereiakes DJ, Robinson JG, Cannon CP. 41.  et al. 2015. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am. Heart J. 169:906–15 [Google Scholar]
42. Cannon CP, Cariou B, Blom D. 42.  et al. 2015. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur. Heart J. 36:1186–94 [Google Scholar]
43. Bays H, Gaudet D, Weiss R. 43.  et al. 2015. Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial. J. Clin. Endocrinol. Metab. 100:3140–48 [Google Scholar]
44. Farnier M, Jones P, Severance R. 44.  et al. 2016. Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerosis 244:138–46 [Google Scholar]
45. Moriarty PM, Parhofer KG, Babirak SP. 45.  et al. 2016. Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: rationale and design of the ODYSSEY ESCAPE trial. J. Clin. Lipidol. 10:627–34 [Google Scholar]
46. Teramoto T, Kobayashi M, Uno K. 46.  et al. 2016. Efficacy and safety of alirocumab in Japanese subjects (phase 1 and 2 studies). Am. J. Cardiol. 118:56–63 [Google Scholar]
47. Kastelein JJ, Ginsberg HN, Langslet G. 47.  et al. 2015. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur. Heart J. 36:2996–3003 [Google Scholar]
48. Ginsberg HN, Rader DJ, Raal FJ. 48.  et al. 2016. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg/dl or higher. Cardiovasc. Drugs Ther. 30:473–83 [Google Scholar]
49. Ridker PM, Tardif JC, Amarenco P. 49.  et al. 2017. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N. Engl. J. Med. 376:1517–26 [Google Scholar]
50. Ballantyne CM, Neutel J, Cropp A. 50.  et al. 2015. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am. J. Cardiol. 115:1212–21 [Google Scholar]
51. Ridker PM, Revkin J, Amarenco P. 51.  et al. 2017. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N. Engl. J. Med. 376:1527–39 [Google Scholar]
52. 52. Pfizer. 2016. Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor News release. http://www.pfizer.com/news/press-release/press-release-detail/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor [Google Scholar]
53. Sahebkar A, Di Giosia P, Stamerra CA. 53.  et al. 2016. Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms. Br. J. Clin. Pharmacol. 81:1175–90 [Google Scholar]
54. Mihaylova B, Emberson J, Blackwell L. 54.  et al. 2012. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380:581–90 [Google Scholar]
55. Everett BM, Smith RJ, Hiatt WR. 55.  2015. Reducing LDL with PCSK9 inhibitors—the clinical benefit of lipid drugs. N. Engl. J. Med. 373:1588–91 [Google Scholar]
56. Nicholls SJ, Puri R, Anderson T. 56.  et al. 2016. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316:2373–84 [Google Scholar]
57. Sabatine MS, Giugliano RP, Wiviott SD. 57.  et al. 2015. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372:1500–9 [Google Scholar]
58. Koren MJ, Sabatine MS, Giugliano RP. 58.  et al. 2017. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. JAMA Cardiol. 2:598–607 [Google Scholar]